Stockreport

First Wave BioPharma Changes Name to Entero Therapeutics

First Wave BioPharma, Inc.  (FWBI) 
PDF Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is [Read more]